The use of PowerPoint to create posters is the weapon of choice for smart researchers. Choose from this selection of horizontally and vertically oriented PowerPoint shows with branded backgrounds, or ...

Poster presentations may not seem as prestigious ... have a chance to promote your poster through an extremely brief oral presentation. Creating your poster Typically, the scientists who attend ...

Using a pre-made PowerPoint document/template helps ensure that your poster gets off to the right start and can speed up production and eliminate questions regarding setup. A variety of templates are ...

If you’ve been in the classroom these past few years, there’s a good chance you’ve heard a peer or coach recommend Canva, the ...

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...

Full abstracts accepted as poster presentations will also be included in the special CTAD edition of the Journal of Prevention of Alzheimer’s Disease (JPAD), the official journal of the CTAD ...

Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies in oncology and ...

The details of the presentations are as follows ... non-medicated subjects. Oral Poster Presentation Title: Clinical Performance of a Novel Point-of-Care Coagulometer for the DOACs Presenter ...

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Perosphere (Perosphere Technologies Inc.), a private medical technologies company focused on developing next-generation coagulation diagnostics, today announced its participation on the agenda of the ...

Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows ...